[go: up one dir, main page]

HUP0000695A2 - Benzodioxol-, benzofurán-, dihidrobenzofurán- és benzodioxánszármazékok és ezeket tartalmazó melatonerg gyógyszerkészítmények - Google Patents

Benzodioxol-, benzofurán-, dihidrobenzofurán- és benzodioxánszármazékok és ezeket tartalmazó melatonerg gyógyszerkészítmények

Info

Publication number
HUP0000695A2
HUP0000695A2 HU0000695A HUP0000695A HUP0000695A2 HU P0000695 A2 HUP0000695 A2 HU P0000695A2 HU 0000695 A HU0000695 A HU 0000695A HU P0000695 A HUP0000695 A HU P0000695A HU P0000695 A2 HUP0000695 A2 HU P0000695A2
Authority
HU
Hungary
Prior art keywords
group
alkyl
dihydrobenzofuran
benzofuran
hydrogen
Prior art date
Application number
HU0000695A
Other languages
English (en)
Inventor
John D. Catt
Graham Johnson
Daniel J. Keavy
Ronald J. Mattson
Michael F. Parker
Katherine S. Takaki
Joseph P. Yevich
Original Assignee
Bristol-Myers Squibb Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Co. filed Critical Bristol-Myers Squibb Co.
Publication of HUP0000695A2 publication Critical patent/HUP0000695A2/hu
Publication of HUP0000695A3 publication Critical patent/HUP0000695A3/hu
Publication of HU226524B1 publication Critical patent/HU226524B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02—Seven-membered rings
    • C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

A találmány (I) általános képletű új benzodioxol,benzofurán, 2,3-dihidrobenzofurán és benzodioxán vegyületekrevonatkozik, amelyek melatonerg szerekként alkalmazhatók, a képletbenQ1 és Q2 jelentése egymástól függetlenül hidrogénatom vagyhalogénatom; X jelentése CH2, CH csoport vagy oxigénatom; Y jelentése.CR3, CR3R4 vagy (CH2)n általános képletű csoport, ebben n értéke 1,2, 3 vagy 4; Z jelentése CH2, CH csoport vagy oxigénatom; R jelentésehidrogénatom, halogénatom vagy alkilcsoport mindkét esetben; m értéke1 vagy 2; R1 jelentése alkilcsoport, cikloalkilcsoport, halogénalkil-csoport, alkilamino-csoport, alkenilcsoport, alkoxialkil-csoport,alkiltioalkil-csoport vagy trifluormetilalkil-csoport; R2 jelentésehidrogénatom vagy alkilcsoport; és R3 és R4 jelentése egymástólfüggetlenül hidrogénatom vagy alkilcsoport. A találmány továbbitárgyát képezik a fenti vegyületeket tartalmazó gyógyszerkészítmények,amelyek alvási rendellenességek ellen hatásosak. Ó
HU0000695A 1996-12-10 1997-12-09 Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane derivatives and the use thereof for producing pharmaceutical compositions having melatonergic activity HU226524B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3268996P 1996-12-10 1996-12-10
PCT/US1997/022627 WO1998025606A1 (en) 1996-12-10 1997-12-09 Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents

Publications (3)

Publication Number Publication Date
HUP0000695A2 true HUP0000695A2 (hu) 2001-05-28
HUP0000695A3 HUP0000695A3 (en) 2002-09-30
HU226524B1 HU226524B1 (en) 2009-03-30

Family

ID=21866306

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000695A HU226524B1 (en) 1996-12-10 1997-12-09 Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane derivatives and the use thereof for producing pharmaceutical compositions having melatonergic activity

Country Status (25)

Country Link
US (3) US5856529A (hu)
EP (1) EP1027043B1 (hu)
JP (1) JP4290765B2 (hu)
KR (1) KR100499106B1 (hu)
CN (1) CN1152679C (hu)
AR (1) AR010346A1 (hu)
AT (1) ATE281833T1 (hu)
AU (1) AU719994B2 (hu)
BR (1) BR9713690B1 (hu)
CA (1) CA2274183C (hu)
CY (1) CY2501B1 (hu)
CZ (1) CZ297673B6 (hu)
DE (1) DE69731562T2 (hu)
DK (1) DK1027043T3 (hu)
ES (1) ES2230626T3 (hu)
HU (1) HU226524B1 (hu)
IL (1) IL129999A (hu)
NO (1) NO321450B1 (hu)
NZ (1) NZ335910A (hu)
PL (1) PL190499B1 (hu)
PT (1) PT1027043E (hu)
RU (1) RU2190609C2 (hu)
TW (1) TW476758B (hu)
WO (1) WO1998025606A1 (hu)
ZA (1) ZA9711051B (hu)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9614347D0 (en) * 1996-07-09 1996-09-04 Smithkline Beecham Spa Novel compounds
US6160134A (en) * 1997-12-24 2000-12-12 Bristol-Myers Squibb Co. Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
WO1999062515A1 (en) * 1998-06-05 1999-12-09 Bristol-Myers Squibb Company Heterocyclic cis cyclopropane derivatives as melatonergic agents
WO2001002392A1 (en) * 1999-06-30 2001-01-11 Bristol-Myers Squibb Company Heterocyclic aminopyrrolidine derivatives as melatonergic agents
NZ529033A (en) 2001-05-15 2005-06-24 F Carboxylic acid substituted oxazole derivatives for use as PPAR-alpha and -gamma activators in the treatment of diabetes
JP2005505586A (ja) * 2001-10-04 2005-02-24 ワイス ５−ヒドロキシトリプタミン−６リガンドとしてのクロマン誘導体
US6569894B1 (en) 2001-10-04 2003-05-27 Bristol-Myers Squibb Company Arylalkylbenzofuran derivatives as melatonergic agents
US6737431B2 (en) 2002-03-12 2004-05-18 Bristol-Myers Squibb Company Benzoxazole derivatives as novel melatonergic agents
ATE372990T1 (de) * 2002-07-03 2007-09-15 Hoffmann La Roche Oxazolderivat und deren verwendung als insulinsensibilisatoren
BR0313946A (pt) * 2002-08-30 2005-07-12 Hoffmann La Roche Compostos, processo para a manufatura destes compostos, composições farmacêuticas que compreendem os mesmos, métodos para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppara(alfa) e/ou ppary, utilização dos compostos e/ou do método
RU2296759C2 (ru) * 2002-09-12 2007-04-10 Ф.Хоффманн-Ля Рош Аг N-замещенные 1н-индол-5-пропионовые кислоты, фармацевтическая композиция, содержащая эти соединения, и их применение (варианты)
ES2312819T3 (es) * 2002-11-25 2009-03-01 F. Hoffmann-La Roche Ag Derivados de indolilo.
US7145478B2 (en) * 2002-12-17 2006-12-05 Evolution Robotics, Inc. Systems and methods for controlling a density of visual landmarks in a visual simultaneous localization and mapping system
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
KR20090024140A (ko) 2006-05-22 2009-03-06 반다 파마슈티칼즈, 인코퍼레이티드. 우울증 질환에 대한 치료
RU2488392C2 (ru) * 2006-05-22 2013-07-27 Ванда Фармасьютиклз, Инк. Лечение агонистом мелатонина
JP5289308B2 (ja) 2007-04-26 2013-09-11 武田薬品工業株式会社 二環性化合物およびその医薬用途
US7964430B2 (en) * 2007-05-23 2011-06-21 Applied Materials, Inc. Silicon layer on a laser transparent conductive oxide layer suitable for use in solar cell applications
EP2195462B1 (en) * 2007-09-13 2013-06-12 Vanda Pharmaceuticals Inc. Prediction of sleep parameter and response to sleep-inducing compound based on per3 vntr genotype
EP2453891A1 (en) 2009-07-16 2012-05-23 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
EP2287159A1 (en) * 2009-07-29 2011-02-23 V.Mane Fils New bicyclic dioxanes, their preparation and their use as organoleptic compounds
UA108510C2 (xx) * 2010-09-22 2015-05-12 Eisai R&D Man Co Ltd Циклопропанова сполука
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
RU2650647C2 (ru) 2012-01-26 2018-04-16 Ванда Фармасьютиклз Инк. Лечение нарушений циркадного ритма
AU2013262631B2 (en) * 2012-05-18 2016-02-04 Vanda Pharmaceuticals Inc. Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl) cyclopropyl]methyl]propanamide
AR091699A1 (es) 2012-07-10 2015-02-25 Astellas Pharma Inc Derivado de indol carboxamida
WO2014010603A1 (ja) 2012-07-10 2014-01-16 アステラス製薬株式会社 腹圧性尿失禁又は混合型尿失禁の治療又は予防用医薬組成物、及び該医薬組成物に含有される化合物のスクリーニング方法
BR112015014619A2 (pt) 2012-12-18 2017-07-11 Vanda Pharmaceuticals Inc tratamento de transtornos do ritmo circadiano
US9643947B2 (en) 2013-08-28 2017-05-09 Northwestern University 7-membered fused heterocycles and methods of their synthesis
WO2015047113A1 (en) * 2013-09-30 2015-04-02 Polfarmex S.A. Novel substituted n, n-dimethylaminoalkyl ethers of isoflavanone oximes as η1-receptor antagonists
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
WO2015117048A1 (en) 2014-01-31 2015-08-06 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
JP6921534B2 (ja) 2014-02-12 2021-08-18 バンダ・ファーマシューティカルズ・インコーポレイテッドＶａｎｄａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 高純度医薬品等級タシメルテオン
US12304896B2 (en) 2014-12-04 2025-05-20 Vanda Pharmaceuticals Inc. Highly purified pharmaceutical grade tasimelteon
KR20240015729A (ko) 2014-09-02 2024-02-05 반다 파마슈티칼즈, 인코퍼레이티드. 스미스 마제니스 증후군을 치료하기 위한 타시멜테온
CN104327022B (zh) * 2014-10-17 2015-12-02 苏州明锐医药科技有限公司 他司美琼的制备方法
CN104402849B (zh) * 2014-11-11 2016-11-09 苏州莱克施德药业有限公司 他司美琼中间体的新制备工艺
CN106588841B (zh) * 2015-10-19 2019-01-25 富乐马鸿凯（大连）医药有限公司 合成2,3-二氢-1-苯并呋喃-4-甲醛的方法
EP3452020A4 (en) 2016-05-06 2020-02-19 Physician's Seal, LLC BALDRIAN COMPOSITION AND RELATED PROCEDURES
CN105949153B (zh) * 2016-05-10 2018-03-02 浙江工业大学 一种他司美琼的合成方法
CN107365288A (zh) * 2016-05-12 2017-11-21 浙江京新药业股份有限公司 他司美琼的晶型
US9944616B2 (en) 2016-06-08 2018-04-17 Apotex Inc. Processes for the preparation of Tasimelteon and intermediates thereof
CN106543119B (zh) * 2016-09-22 2019-07-26 浙江工业大学 一种光学纯他司美琼的制备方法
BR102016024814A2 (pt) 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
WO2018149940A1 (en) 2017-02-17 2018-08-23 Quimica Sintetica, S. A. Process for the preparation of enantiomerically enriched dihydrobenzofurans and intermediate compounds obtained in the process
US20210059973A1 (en) 2017-08-02 2021-03-04 Vanda Pharmaceuticals Inc. Treatment of Affective Disorders
WO2019173180A1 (en) * 2018-03-04 2019-09-12 Vanda Pharmaceuticals Inc. Treatment of disorders with tasimelteon
AU2019337627A1 (en) * 2018-09-12 2021-04-01 Vanda Pharmaceuticals Inc.. Improving sleep or post-sleep performance
TWI834874B (zh) 2019-05-15 2024-03-11 日商衛材R&D企管股份有限公司 對於食慾素-2受體拮抗劑之製備有用之方法及化合物、以及雜質少之萊博雷生
ES3020034T3 (en) 2019-06-29 2025-05-21 Vanda Pharmaceuticals Inc Tasimelteon use in treating sleep aberrations
CA3161975A1 (en) * 2019-12-13 2021-06-17 Vanda Pharmaceuticals Inc. Liquid tasimelteon formulations and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071875A (en) * 1989-09-25 1991-12-10 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2667316B1 (fr) * 1990-10-02 1994-09-16 Roussel Uclaf Nouveaux derives du benzofuranne, leur procede de preparation et leur application comme pesticides.
FR2674524B1 (fr) * 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680507B1 (fr) * 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2689124A1 (fr) * 1992-03-27 1993-10-01 Adir Nouvelles naphtylalkylamines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
FR2696453B1 (fr) * 1992-10-02 1994-12-23 Adir Nouveaux arylalkyl(thio)amides, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent.
GB9326192D0 (en) * 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
GB9407919D0 (en) * 1994-04-21 1994-06-15 Glaxo Group Ltd Chemical compounds
FR2725985B1 (fr) * 1994-10-21 1996-11-15 Adir Nouveaux composes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5633218A (en) * 1995-05-24 1997-05-27 E. I. Du Pont De Nemours And Company Herbicidal benzodioxoles and benzodioxanes
US5596019A (en) * 1995-06-07 1997-01-21 Bristol-Myers Squibb Company N-acyl-cycloalkylamine derivatives as melatonergics
CA2176854A1 (en) * 1995-06-07 1996-12-08 Daniel J. Keavy N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
PT901483E (pt) * 1996-05-14 2003-11-28 Glaxo Group Ltd Benzofuranos e benzopiranos como agentes cronobiologicos

Also Published As

Publication number Publication date
ZA9711051B (en) 1999-06-09
NO321450B1 (no) 2006-05-15
CY2501B1 (en) 2005-09-02
DE69731562D1 (de) 2004-12-16
ATE281833T1 (de) 2004-11-15
US5981571A (en) 1999-11-09
IL129999A (en) 2004-06-20
TW476758B (en) 2002-02-21
PL190499B1 (pl) 2005-12-30
HUP0000695A3 (en) 2002-09-30
NZ335910A (en) 2000-11-24
AU5598598A (en) 1998-07-03
KR20000069396A (ko) 2000-11-25
HK1029947A1 (en) 2001-04-20
ES2230626T3 (es) 2005-05-01
NO992804L (no) 1999-08-09
PT1027043E (pt) 2005-02-28
JP2001505916A (ja) 2001-05-08
US5856529A (en) 1999-01-05
CA2274183A1 (en) 1998-06-18
NO992804D0 (no) 1999-06-09
PL333950A1 (en) 2000-01-31
EP1027043B1 (en) 2004-11-10
RU2190609C2 (ru) 2002-10-10
CN1152679C (zh) 2004-06-09
DK1027043T3 (da) 2005-01-10
BR9713690A (pt) 2000-05-02
CZ297673B6 (cs) 2007-02-28
EP1027043A4 (en) 2002-02-20
CN1239886A (zh) 1999-12-29
CA2274183C (en) 2006-10-24
KR100499106B1 (ko) 2005-07-01
DE69731562T2 (de) 2005-11-24
EP1027043A1 (en) 2000-08-16
BR9713690B1 (pt) 2009-08-11
AR010346A1 (es) 2000-06-07
IL129999A0 (en) 2000-02-29
CZ199199A3 (cs) 1999-09-15
AU719994B2 (en) 2000-05-18
HU226524B1 (en) 2009-03-30
JP4290765B2 (ja) 2009-07-08
US6060506A (en) 2000-05-09
WO1998025606A1 (en) 1998-06-18

Similar Documents

Publication Publication Date Title
HUP0000695A2 (hu) Benzodioxol-, benzofurán-, dihidrobenzofurán- és benzodioxánszármazékok és ezeket tartalmazó melatonerg gyógyszerkészítmények
DE69503803D1 (de) 3,5-dioxo-(2h,4h)-1,2,4-triazinderivate ihre herstellung und verwendung als medikament
HUP0004492A2 (hu) Fundális relaxációs tulajdonságokkal rendelkező benzodioxán-, benzofurán- vagy benzopirán-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
HUP0001192A2 (hu) Topiramát és származékainak alkalmazása elhízás kezelésére használható gyógyszerkészítmények előállítására
HUP9902471A2 (hu) Piperazin- és piperidinvegyületek, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
DE69505968D1 (de) Azolidindion-derivate und ihre anwendung als antihyperglykämika
ES2096073T3 (es) Derivado de benzamida.
AU5984086A (en) New derivatives of 2,3-dihydro benzofuran, their preparation and the pharmaceutical compositions containing them
MY113427A (en) Anti-neurodegeneratively active 10-aminoaliphatyl- dibenz [b,f] oxepines
HUP9904294A2 (hu) Topiramát származékok alkalmazása neuropátiás fájdalom kezelésére alkalmas gyógyszer előállítására
HUP0102522A2 (hu) 3',3'-N-bisz-helyettesített makrolid LHRH antagonista vegyületek és alkalmazásuk, eljárás előállításukra, valamint e vegyületeket tartalmazó gyógyászati készítmények
ATE26443T1 (de) 4-aroylimidazolidin-2-one.
ES543802A0 (es) Procedimiento de preparacion de nuevos derivados a-etilben- zol con un grupo n-carbamiloxi sustituido
NO20005932L (no) Nye forbindelser avledet fra <alfa>-D-xylose, og deres fremstilling og terapeutiske bruk
ATE36520T1 (de) Polyprenylverbindung, ihre herstellung und pharmazeutische verwendung.
ATE146463T1 (de) Säureanhydride, ihre herstellung und ihre verwendung
SE8302076L (sv) Nya imidazolkinoxaliner och deras salter, framstellning derav, anvendning derav sasom lekemedel, kompositioner innehallande dem och de erhallna mellanprodukterna
NO151934C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 4-amino-2,6-diaryl-tetrahydrotiopyraner
SE8804436D0 (sv) Trombolytiska och liknande sammansaettningar
JO1825B1 (en) Therapeutic agents
ES2036594T3 (es) Piperidinas, o azepinas substituidas, su preparacion y su aplicacion en terapeutica.